## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.93 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-1.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($89.50)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Argus Research Adjusts Zimmer Biomet Price Target to $125 From $135, Maintains Buy Rating**
- Source: marketscreener.com | 20251205T130810 | Somewhat-Bullish | Relevance: 100%
- Argus Research has adjusted its price target for Zimmer Biomet Holdings, Inc. to $125, down from $135, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst actions on the company, although Argus Research's outlook remains positive. The article also provides recent news headlines related to Zimmer Biomet's business activities and other analyst target changes.

**2. Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors**
- Source: MarketWatch | 20251203T170900 | Somewhat-Bearish | Relevance: 100%
- Zimmer Biomet Holdings Inc. (ZBH) shares fell 1.10% to $93.10 on Wednesday, marking its fourth consecutive day of losses. This occurred despite a generally positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains.

**3. Why Is Zimmer (ZBH) Up 5.3% Since Last Earnings Report?**
- Source: www.sharewise.com | 20251205T182804 | Somewhat-Bullish | Relevance: 100%
- Zimmer Biomet (ZBH) saw its shares rise 5.3% since its last earnings report, outperforming the S&P 500. The company reported Q3 2025 adjusted earnings of $1.90 per share, beating estimates, despite revenues of $2.00 billion missing the Zacks Consensus Estimate. Zimmer also updated its 2025 financial guidance, narrowing its constant currency revenue growth expectations.

**4. New York State Common Retirement Fund Sells 14,798 Shares of Zimmer Biomet Holdings, Inc. $ZBH**
- Source: MarketBeat | 20251204T121527 | Neutral | Relevance: 100%
- The New York State Common Retirement Fund has reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.1%, selling 14,798 shares and now owning 166,965 shares valued at approximately $15.23 million. This comes as Zimmer Biomet beat its quarterly EPS estimates but slightly missed revenue expectations, setting FY2025 guidance. Analyst sentiment for the stock is mixed, with a consensus "Hold" rating and an average price target of $109.

**5. Zimmer Biomet (NYSE: ZBH) SVP Lori Winkler Details RSU Vesting and Tax Withheld Shares**
- Source: Stock Titan | 20251204T000837 | Neutral | Relevance: 100%
- Zimmer Biomet Holdings SVP and CHRO Lori Winkler reported the vesting of restricted stock units (RSUs) on November 28, 2025, involving 56.534 and 122.695 shares each, which were settled into common stock at an exercise price of $0. Simultaneously, an equal number of shares were withheld at $97.52 per share to cover FICA and tax obligations due to her retirement eligibility. Following these transactions, Winkler directly holds 6,833 shares, with remaining RSUs vesting in March 2026 and February 2026/2027.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 7)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Canaccord Genui | $93 | $101 | -8% |
| 2025-11-06 | UBS | $88 | $96 | -8% |
| 2025-11-06 | RBC Capital | $101 | $111 | -9% |
| 2025-11-06 | Barclays | $104 | $105 | -1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Canaccord Genui | main | Hold |
| 2025-11-06 | UBS | main | Sell |
| 2025-11-06 | RBC Capital | main | Outperform |
| 2025-11-06 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Forward P/E 11.1x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (7 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.0B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 11.1 |
| Current P/E | 11.5 |
| YoY Growth | 4.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.7% to 0.2% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.8pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 50. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.17% (CS: 55) | Neutral |
| RSI_14 | 50.0 | Neutral |
| MACD Histogram | 0.49 | Bullish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 0.979x | Below |
| vs SMA200 | 0.953x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $94.28
- **Stop Loss:** $89.50 (5.1% risk)
- **Target:** $103.84 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 104
- **Position Value:** $9,805.12
- **Portfolio %:** 9.81%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*